<DOC>
	<DOCNO>NCT00949559</DOCNO>
	<brief_summary>This study do : - Test safety EP-100 see effect ( good bad ) patient cancer ; - Find high dose EP-100 give without cause bad side effect ; - Examine much EP-100 blood certain time give quickly body get rid ; - Observe whether effect EP-100 size activity cancer patient 's body .</brief_summary>
	<brief_title>Pharmacodynamics ( PD ) Pharmacokinetics ( PK ) Study EP-100 Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Subjects histologically confirm solid carcinoma Subjects whose tumor express LHRH receptor tumor biopsy Tumor progression receive standard/approved chemotherapy approve therapy One metastatic tumor measurable CT scan evaluable disease Karnofsky performance â‰¥ 70 % Life expectancy least 3 month Age great equal 18 year Signed , write informed consent . Consent must provide prior perform studyrelated procedure . A negative pregnancy test ( female ) Acceptable liver function Acceptable renal function Serum creatinine within normal limit , OR calculate creatinine clearance great equal 60 mL/min/1.73 m2 subject creatinine level institutional normal . Acceptable hematologic status : No clinically significant abnormality Acceptable coagulation status : For men woman childproducing potential , use effective contraceptive method study New York Heart Association Class III IV , cardiac disease , myocardial infarction within past 6 month , unstable arrhythmia , evidence ischemia ECG Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Pregnant nursing woman . NOTE : Women child bear potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Treatment radiation therapy investigational therapy within 4 week prior Day 1 . Had receive chemotherapy prior study entry equivalent within 3 5 halflives chemotherapy agent 4 week prior study entry ( whichever short ) resolution side effect previous therapy ( 6 week nitrosoureas Mitomycin C ) . Subjects active CNS metastasis exclude . Subjects history CNS metastases eligible treat stable without symptom 4 week completion treatment , image documentation require , must steroids . Had major surgery , diagnostic surgery , within 4 week prior Day 1 Had minor surgery within 2 week prior Day 1 Patients may benefit hormonal treatment breast cancer patient whose tumor hormone receptor positive ( ER/PR ) without rapidly progressive visceral disease patient prostate cancer hormonal manipulation therapy . Patients potentially lifethreatening disease ( hypercalcemia , spinal cord compression ) whose disease may acutely progress EP100 administration cause flare reaction . Unwillingness inability comply procedure require protocol Known infection HIV , hepatitis B , hepatitis C Subjects susceptible histamine release ( e.g . patient mastocytosis , mastocytoma , mast cell leukemia , asthma , hay fever , allergic disorder disorder increase mast cell number ) . Patients chronic treatment corticosteroid . Baseline QTc exceed 450 msec ( use Bazetts formula ) and/or patient receive class 1A class III antiarrythmic agent . Serious nonmalignant disease ( e.g. , hydronephrosis , liver failure , condition ) could compromise protocol objective opinion investigator and/or sponsor Subjects currently receive investigational agent Subjects use LHRH agonist ( leuprolide [ Lupron , Eligard ] , buserelin [ Suprefact , Suprecor ] , nafarelin [ Synarel ] , histrelin [ Supprelin ] , goserelin [ Zoladex ] , deslorelin [ Suprelorin , Ovuplant ] , Triptorelin others ) antagonist ( Abarelix [ Plenaxis ] , Cetrorelix [ Cetrotide ] , Ganirelix [ Antagon ] others ) prior study treatment . If LHRH agonist use , 4week washout period recommend .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>